Mastelli & DermaFocus: The Reliable Framework Behind Plinest®

As regenerative aesthetics continues to develop, medical professionals are placing increasing emphasis on manufacturing standards, purification processes, clinical evidence, and distribution governance when assessing injectable treatments.

Within this context, Plinest® is a polynucleotide-based injectable developed by Mastelli and distributed exclusively in the UK and Ireland by DermaFocus.

The collaboration between Mastelli and DermaFocus provides a structured framework that supports the safe, consistent, and responsible use of Plinest® within medical aesthetic practice.

Mastelli: established experience in polynucleotide science

Mastelli has worked with polynucleotides since the mid-20th century, with applications spanning dermatology, wound repair, ophthalmology, and tissue regeneration. This background informs the development of its aesthetic polynucleotide formulations, which are manufactured using pharmaceutical-grade processes rather than cosmetic production standards.

The company’s ongoing involvement in research, formulation development, and manufacturing underpins the design of the Plinest® range as a regenerative injectable intended for medical use.

PN-HPT: purification and biocompatibility

Plinest® is produced using PN-HPT™ (Polynucleotides High Purification Technology), Mastelli’s patented, multi-step purification process developed for medical applications.

Polynucleotides are sourced from trout bred in controlled freshwater environments, using a no-waste production model in which raw materials are fully utilised.

During manufacture, repeated purification stages are applied to remove residual proteins and other impurities, resulting in highly purified polynucleotides with preserved molecular integrity.

This process supports high biocompatibility and consistent interaction with human tissues, particularly relevant in aesthetic practice where treatments may involve delicate anatomical areas or repeated sessions.

Clinical evidence and tolerability

Plinest® is supported by published clinical studies evaluating parameters such as skin hydration, elasticity, texture, and overall dermal quality. These studies, alongside extended clinical use, demonstrate a favourable tolerability profile when the product is used in accordance with recommended protocols.

The emphasis on controlled sourcing and rigorous purification is an important consideration for practitioners seeking predictable tissue response within regenerative treatment plans.

DermaFocus: distribution, training and governance

While Mastelli is responsible for development and manufacture, DermaFocus oversees distribution and clinical support for Plinest® in the UK and Ireland. This ensures that the product is supplied exclusively to appropriately qualified medical professionals and supported by structured education and guidance.

DermaFocus provides:

• Medical-only distribution
• Practitioner training on indications, techniques, and protocols
• Product traceability and correct storage
• Ongoing clinical support and governance

This framework supports consistent and responsible integration of Plinest® into medical aesthetic practice.

Why the Mastelli-DermaFocus framework matters

In a rapidly expanding regenerative aesthetics market, variation in product quality, sourcing, and training standards presents challenges for clinicians. The Mastelli-DermaFocus partnership addresses these considerations through:

• Pharmaceutical-level manufacturing processes
• Controlled sourcing and purification
• Defined distribution and education pathways
• Ongoing clinical oversight

Together, these elements support informed decision-making when introducing polynucleotide injectables into a clinical portfolio.